Advanced Search

An Evaluation of the Cost Effectiveness of Drotrecogin Alfa (Activated) Relative to the Number of Organ System Failures

Contents:

Author Info

  • Madeline Betancourt

    (College of Pharmacy, Wayne State University, Detroit, Michigan, USA)

  • Peggy S. McKinnon

    (Department of Pharmacy Services, Detroit Receiving Hospital, Detroit, Michigan, USA, Anti-Infective Research Laboratory, College of Pharmacy, Wayne State University, Detroit, Michigan, USA)

  • R. Michael Massanari

    (Center for Health Effectiveness Research, Wayne State University, Detroit, Michigan, USA)

  • Salmaan Kanji

    (College of Pharmacy, Wayne State University, Detroit, Michigan, USA)

  • David Bach

    (Detroit Medical Center, Detroit, Michigan, USA)

  • John W. Devlin

    (School of Pharmacy, Northeastern University, Boston, Massachusetts, USA)

Registered author(s):

    Abstract

    Background: While drotrecogin alfa (activated) was shown to decrease absolute 28-day mortality by 6.1% in patients with severe sepsis in the Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, no mortality benefit was observed in the subset of patients with only one organ system failure. Consequently, some institutions restrict drotrecogin alfa (activated) use to patients with severe sepsis with >=2 organ system failures. Objective: To measure the cost effectiveness of drotrecogin alfa (activated) for treatment of severe sepsis in relation to the number of organ system failures and determine the economic impact of restricting drotrecogin alfa (activated) use based on the number of organ system failures. Perspective: Policy perspective specific to our 340-bed, level I trauma centre. Methods: A Monte Carlo simulation analysis was conducted to evaluate a hypothetical cohort of 10 Results: With increasing number of organ system failures, the proportion of lives saved with drotrecogin alfa (activated) increased, and consequently the ICER decreased. Restriction of drotrecogin alfa (activated) to patients with >=4 organ system failures was the most cost-effective scenario (0.11 lives saved; $US56 Conclusion: While restriction of drotrecogin alfa (activated) use to patients with sepsis with >=4 organ system failures is the most cost-effective alternative, restriction to those with >=2 organ system failures is the preferred alternative for our institution according to the number of lives saved and available financial resources.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/pdfhandler.00019053-200321180-00003.pdf
    Download Restriction: Pay per view
    File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/fulltext.00019053-200321180-00003.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

    Volume (Year): 21 (2003)
    Issue (Month): 18 ()
    Pages: 1331-1340
    Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
    Handle: RePEc:wkh:phecon:v:21:y:2003:i:18:p:1331-1340

    Contact details of provider:
    Web page: http://pharmacoeconomics.adisonline.com/

    For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).

    Related research

    Keywords: Cost-effectiveness; Drotrecogin-alfa; Sepsis;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:21:y:2003:i:18:p:1331-1340

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.